Description

This track will focus on HIV infection and replication, transmission, genetics, evolution, structure and function, pathogenesis, adaptive and innate immune responses to HIV, genetic susceptibility to HIV, the interaction of micronutrients, co-infection and progress in animal models. Highlights will include novel insights into the nature of HIV, intersections between the HIV and COVID-19 pandemics, and progress towards understanding the drivers and implications of ongoing immuno-metabolism including the impact of COVID-19 on people living with HIV.

Abstract Categories

Immunology of HIV

A1. Innate immune responses and function in the natural history of HIV infection
A2. Immune responses in resistant cohorts: elite controllers and exposed uninfected

TRANSMISSION AND PATHOGENESIS (HIV-1/2), TB
A3. HIV transmission (mucosal and mother to child transmission; other transmissions)
A4. Ageing and HIV
A5. Zoonotic TB

Host genetics and HIV infections

A6. Host genetics of resistance and susceptibility and restriction factors

HIV: Co-infections and emerging pathogens
A7. HIV co-infection with TB and other pathogens (Hepatitis B, C, HPV, bacterial agents)
A8. HIV interactions with emerging and other opportunistic pathogens

HIV: Drug development and resistance

A9. HIV drug development: Synthetic, traditional and microbicides
A10. Targeting and HIV persistence during ART (cure strategies)

Vaccine development

A11. Clinical trials in HIV vaccine development
A12. Animal models for vaccine development

Diagnostics tools development (for use in resource-limited settings)

A13. Novel assays and cost-effective tools for virological monitoring
A14.  Rapid and cost-effective HIV screening and diagnostic methods
A15. HIV drug resistance testing

Characterization of HIV latency and viral reservoir
A16. Targeting and eradication of reservoirs

COVID-19

A17. Basic science, pathogenesis, virology, immunology, inflammation
A18. COVID-19 Vaccine

TB
A19. Basic Science, pathogenesis of TB – pathogen and host

Description

Clinical science will focus on research developments in the clinical care of people living with HIV, with emphasis on new-generation ART, including long-acting orals and injectable, and treatment strategies involving two-drug regimens and long-acting formulations. Clinical research on populations most vulnerable to HIV acquisition, such as adolescents, transgender populations and women, will continue to be a focus of Track B. It will highlight insights into the intersection of HIV and ageing, including approaches for the treatment of HIV and management of HIV-related co-morbidities, co-infections and complications. Finally, Track B will address the impact of the COVID-19 pandemic on diagnosis, linkage to care and retention and the clinical impact on people living with HIV.

Abstract Categories

The clinical course of HIV infection and disease
B1 Morbidity and mortality/life expectancy during ART
B2. Acute and early HIV infection, meeting the new targets (95-95-95)

B3. TB treatment outcomes

Diagnosis and management of co-infections/co-morbidities

B4. Co-infections (TB, Hepatitis, STIs, Cryptococcus, bacterial diseases, leishmaniosis, Malaria and others)
B5Tools for diagnosis and management of infections: point of care
B6. Diagnosis and management of STIs

B7. Laboratory diagnosis of TB

B8. Sample Transportaion(HIV/TB)

HIV and Non Communicable Diseases

B9. Diabetes, cardiovascular, renal diseases, bone mineral diseases, HIV and neurocognitive disorders

Antiretroviral therapy
B10. Management of HIV infection in Key Populations
B11. Antiretroviral therapy to prevent HIV-Transmission

Palliative care and nutrition
B12. Home and community-based care and support
B13. Other Strategies and Therapies (traditional medicine, spiritual care)

Clinical guidelines, tools and algorithms

B14. Country adaptation of global HIV diagnosis and treatment guidelines

COVID-19
B15. Innovation in Service delivery approaches

Description

This track will focus on HIV and AIDS prevention research and issues related to the design, implementation and evaluation of prevention programs to reach the SDG. It will include examination of research, methodological and programmatic advances in the continuum of prevention, particularly best practices in HIV prevention for vulnerable populations in resource-limited settings. Strategies to put HIV prevention research into practice, efforts to promote preparedness for bio-medical prevention technologies, and research on new prevention approaches including microbicides, vaccines, pre-and post-exposure prophylaxis, and other methods will be presented. This Track will also address co-morbidities (Hepatitis, Tuberculosis, and STIs, non-communicable and emerging diseases). The track will also assess best practices for greater inclusion of key groups such as the “missing men”, adolescent girls and young women, marginalized and refugee populations, people who use drugs, men who have sex with men, transgender people and Indigenous peoples. A major focus will also be on next-generation HIV prevention trial designs, which can assess new advances in the context of high-efficacy options.

Abstract Categories

Basic HIV Epidemiology
C1. Epidemiology of HIV in youth, adolescents and children

Epidemiology of HIV co‐morbidity and emerging diseases
C2. HIV and non‐communicable diseases (cardiovascular risk, metabolic diseases, mental health, reproductive health, etc.)
C3. HPV infections and cancers in people living with HIV
C4. HIV, Opportunistic Infections (OI) and the epidemiology of emerging diseases

Social Epidemiology of HIV
C5. Gender-based violence and HIV transmission

HIV/AIDS Surveillance and Monitoring and Evaluation

C6. Modelling HIV epidemic in the advent of ART, where does monitoring and evaluation fit?
C7 Surrogate markers: What remains of the measurement of CD4 T lymphocytes in a situation of accessibility of the viral load?

Methodological Issues and Capacity‐Building in Epidemiological and Prevention Research
C8. Measuring and modelling the impact of prevention and treatment interventions on the HIV epidemic at the population level.
C9. Methods aimed at measuring the impact of the HIV epidemic, recent HIV infections and HIV incidence

HIV/AIDS Prevention Programmes
C10. Prevention programmes in institutional and community settings
C11. Prevention programmes for immigrants, mobile and displaced populations
C12. New approaches for HIV prevention
C13. Integrating HIV prevention into reproductive health, care, support and treatment programmes

Diversified prevention tools
C14. PrEP
C15. Microbicides

COVID-19
C16. Impact of COVID-19 on HIV response

TB Epidemiology

C. 17. TB epidemiology in children and adults
C.18 TB epidemiology in high risk groups (prisons, mining communities, urban slums etc)
C. 19 TB infection control- Contact Tracing and TB Preventive Therapy
C. 20 TB and COVID
C. 21.MDR-TB

Description

This track aims to highlight new knowledge and address gaps in the translation of behavioural and social science evidence into practice, and contribute to the building of theory and understanding in HIV-related social science. The track also aims to promote understanding of the individual and social determinants of HIV-related risk, vulnerability, and impact to inform the development of effective and sustainable HIV responses based on human dignity and individual entitlements. This track will feature research, analysis and evaluation on psychosocial factors that shape individual attitudes, experiences, and behaviours; social and structural factors that shape vulnerability and risk; social and cultural norms that underlie individual risk and community vulnerability. Additionally, it will address the legal, social and other environmental factors that impede or enable prevention, early diagnosis, access to and sustained engagement with care and treatment, and adherence to ART. Particular focus will be on the impact of these factors on adolescent girls and women and underserved, marginalized and key populations, and on evidence-based policies and initiatives that have proven effective in reducing HIV incidence and the risk of acquisition and transmission. Track D will also explore how we can more effectively establish and support enabling legal environments through law reform and changes in law enforcement practice that are informed by and secure the enjoyment of human rights and ensure that no one is left behind.

Abstract Categories

Human rights, law and ethics (Track sub-title)

D1. Human rights, Protections and HIV services for key and vulnerable populations
D2. Human Rights, Sexual rights and access to citizenship
D3. Ethics, human rights, access to medicines for prevention, treatment and care

D4. TB- related stigma among health care workers and patients

D5. Cost study on TB treatment

Stigma and Discrimination
D6. Stigma, discrimination, key and vulnerable populations affected by HIV
D7. Stigma, social attitudes, media and public debate
D8. Punitive laws, enforcement and HIV risk

SEX, SEXUALITY, GENDER AND MEDIA REPORTING IN HIV

D9. Gender equality, power dynamics and gender equity: Addressing a feminized epidemic
D10. Same-sex- attracted, bisexual and queer people
D11. Femininity, masculinity and transgender issues in HIV
D12. New prevention technologies and Family-centered approach to HIV care and support

Policies, Programs and HIV response

D13. Policy, politics and HIV management
D14. Law enforcement and vulnerable populations
D15. Policies for HIV prevention, diagnosis, treatment, care, protection and support
D16. Policies and socio-economic determinants of vulnerability
D17. Policy M&E, analysis, impact and indicators of policy effectiveness

Social theories and knowledge production
D18. Social, cultural and behavioural science collaboration

Socio-cultural determinants of HIV
D19. Harmful traditional practices and HIV
D20. Sex work, the global recession and HIV
D21. Traditional and complementary approaches in the response to HIV

Structural Determinants of HIV
D22. Poverty, wealth. Income inequalities and HIV
D23. Gender, age, ethnicity, disability and HIV
D24. Economic transitions, socio-cultural changes and HIV risk
D25. Prisons closed settings and HIV

COVID-19
D26. Public Health responses include physical distancing and community level effort, programme policies, lifting restrictions, modelling.
D27. Intersections between COVID-19 and HIV

TRACK E: INTERVENTIONS AND BEST PRACTICES

Description

This track aims to provide new insights into the status of the health systems and their capacity and challenges to expanding treatment and prevention in resource-limited settings. At the same time, issues related to health economics, integration of health programs, country ownership of national health and HIV programs, and advancement of a comprehensive and integrated approach to health and rights will be discussed. This track shows the need for a holistic vision of the fight against the disease by the effective strengthening of health systems.

Abstract Categories

HIV and health system strengthening (Track sub-title)

E1. AIDS investments for health system strengthening
E2. Innovative responses to resource needs for health system strengthening
E3. Procurement and supply chain management
E4. Community systems strengthening for health care delivery
E5. Public health systems and the delivery of HIV care at scale

Management for health care delivery
E6. Integrated HIV service delivery services with non-health response programs
E7. Decentralization, differentiated care and task-shifting

Shared Responsibility, Global Solidarity and the SDGs

E8. Governance – peer review and accountability mechanisms
E9. Sustainable financing options and financial tracking
E10. Capacity strengthening for HIV domestic program funding.

Health economics

E11. Building country-level capacity for quality improvement
E12. Evaluation of integrated models of health service delivery
E13. Health access financing models for HIV service delivery
E. 14 Cost benefit analysis of sample transportation(TB/HIV) using different approaches.
E. 15 Evaluation of the TB surveillance system

Partnership in HIV

E16. Innovative partnership models

Innovation and best practices

E17.Interventions for increase uptake of and retention in HIV services
E18. Public-private partnerships
E19. Technologies for HIV care delivery
E.20. Best Practices to increase TPT uptake
E.21 Best Practices in finding the missing TB cases

COVID-19

E22. Integrated HIV and COVID-19 care
E.23. Bi-directional testing for TB and COVID

TB

E24. Integrated HIV and TB care